Home›Trial›NCT07373639
NCT07373639RECRUITING

A Long-term Follow-up Study in Patients Who Received BEAM-101

Study Summary

This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for 13 years (a total of 15 years after receiving BEAM-101).

Conditions
HemoglobinopathySickle Cell Disease
Interventions / Drugs
Long-Term Follow-up Study of patients who received BEAM-101
View on ClinicalTrials.gov ↗
Sponsor
BEAM
Beam Therapeutics
Base Editing
C51/100
Study Details
Enrollment50 participants
Primary Completion—
Lead SponsorBeam Therapeutics Inc.
Data Retrieved2026-04-11 04:07:17.424746+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 50 participants
Sponsor Catalyst Profile

Beam Therapeutics (BEAM) is the sponsoring company for this trial. BiotechSign currently grades this company C (51/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

BEAM Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.